Impact of early detection on cancer curability: A modified Delphi panel study. PLoS One. 2022; 17(12):e0279227.
View in:
PubMed
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2022 Dec 06.
View in:
PubMed
The NOGO receptor NgR2, a novel aVß3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Sci Rep. 2022 11 07; 12(1):18879.
View in:
PubMed
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951.
View in:
PubMed
Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022 11; 6:e2200382.
View in:
PubMed
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J Clin Invest. 2022 11 01; 132(21).
View in:
PubMed
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Res. 2022 09 02; 82(17):3088-3101.
View in:
PubMed
Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. Eur Urol Focus. 2022 Aug 20.
View in:
PubMed
Future directions for precision oncology in prostate cancer. Prostate. 2022 08; 82 Suppl 1:S86-S96.
View in:
PubMed
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNa ± Bevacizumab: Results from CALGB 90206 (Alliance). Clin Cancer Res. 2022 07 01; 28(13):2771-2778.
View in:
PubMed
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022 05 27; 376(6596):eabe1505.
View in:
PubMed
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer. 2022 Jun; 4(2):zcac016.
View in:
PubMed
Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2022 05; 20 Suppl 9(5):2-8.
View in:
PubMed
Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2022 May; 20 Suppl 9(5):1-20.
View in:
PubMed
Editorial: Metastatic prostate cancer: a wealth of data to put into practice. Curr Opin Urol. 2022 05 01; 32(3):267-268.
View in:
PubMed
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141.
View in:
PubMed
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19.
View in:
PubMed
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Mol Oncol. 2022 06; 16(12):2384-2395.
View in:
PubMed
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022 07; 257(3):274-284.
View in:
PubMed
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022 Mar 01; 28(5):928-938.
View in:
PubMed
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11.
View in:
PubMed
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proc Natl Acad Sci U S A. 2022 01 25; 119(4).
View in:
PubMed
Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2022 03 10; 40(8):818-824.
View in:
PubMed
Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian J Androl. 2022 Jan-Feb; 24(1):116-118.
View in:
PubMed
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. J Biol Chem. 2022 02; 298(2):101556.
View in:
PubMed
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
View in:
PubMed
Towards Biologically Driven Decision-making in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2021 12; 4(6):924-926.
View in:
PubMed
Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Adv Mater. 2022 Jan; 34(2):e2100096.
View in:
PubMed
Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology. Eur Urol. 2022 01; 81(1):48-49.
View in:
PubMed
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nat Commun. 2021 11 04; 12(1):6377.
View in:
PubMed
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int J Cancer. 2022 04 01; 150(7):1166-1173.
View in:
PubMed
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775.
View in:
PubMed
Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021 Sep 13; 5(1):84.
View in:
PubMed
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021 09; 23(9):1023-1034.
View in:
PubMed
Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 11; 258-259:61-68.
View in:
PubMed
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021 Aug 12; 5(1):76.
View in:
PubMed
Prostate cancer. Lancet. 2021 09 18; 398(10305):1075-1090.
View in:
PubMed
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74.
View in:
PubMed
Therapy considerations in neuroendocrine prostate cancer: what next? Endocr Relat Cancer. 2021 07 15; 28(8):T67-T78.
View in:
PubMed
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021 Aug; 30:47-62.
View in:
PubMed
Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021 Jul; 10(7):3104-3116.
View in:
PubMed
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun Biol. 2021 06 24; 4(1):785.
View in:
PubMed
The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021 10 28; 519:20-29.
View in:
PubMed
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021 09 01; 27(17):4923-4936.
View in:
PubMed
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021 06 07; 12(1):3372.
View in:
PubMed
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precis Oncol. 2021 May 26; 5(1):44.
View in:
PubMed
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
View in:
PubMed
Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433.
View in:
PubMed
Activated ALK Cooperates with N-Myc via Wnt/ß-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer Res. 2021 04 15; 81(8):2157-2170.
View in:
PubMed
Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021 09; 24(3):623-637.
View in:
PubMed
Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep. 2021 01 12; 23(2):15.
View in:
PubMed
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2021 09; 155:165-171.
View in:
PubMed
Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020 12 03; 11(1):6195.
View in:
PubMed
Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020 11; 1(11):1041-1053.
View in:
PubMed
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Transl Oncol. 2021 Jan; 14(1):100944.
View in:
PubMed
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat Commun. 2020 11 03; 11(1):5549.
View in:
PubMed
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol. 2021 06; 79(6):722-733.
View in:
PubMed
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open. 2020 10 01; 3(10):e2021692.
View in:
PubMed
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050.
View in:
PubMed
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
View in:
PubMed
Small extracellular vesicles modulated by aVß3 integrin induce neuroendocrine differentiation in recipient cancer cells. J Extracell Vesicles. 2020 May 24; 9(1):1761072.
View in:
PubMed
ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics. 2020 05 01; 36(9):2665-2674.
View in:
PubMed
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990.
View in:
PubMed
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020 04 01; 130(4):1653-1668.
View in:
PubMed
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Mol Cancer Ther. 2020 05; 19(5):1157-1164.
View in:
PubMed
Docetaxel for Early Prostate Cancer: What Have We Learned? Eur Urol. 2020 05; 77(5):573-575.
View in:
PubMed
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343.
View in:
PubMed
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547.
View in:
PubMed
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nat Commun. 2020 01 20; 11(1):384.
View in:
PubMed
Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 04 01; 126(7):1407-1412.
View in:
PubMed
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.
View in:
PubMed
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3.
View in:
PubMed
Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019; 8(12):e1670019.
View in:
PubMed
Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019 11; 16(11):645-654.
View in:
PubMed
The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. Eur Urol. 2019 12; 76(6):729-731.
View in:
PubMed
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precis Oncol. 2019; 3.
View in:
PubMed
Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019 11; 121:7-18.
View in:
PubMed
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6839-6851.
View in:
PubMed
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proc Natl Acad Sci U S A. 2019 08 20; 116(34):16987-16996.
View in:
PubMed
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO Precis Oncol. 2019; 3.
View in:
PubMed
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019 12 01; 25(23):6916-6924.
View in:
PubMed
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
View in:
PubMed
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 2019 07 01; 129(9):3924-3940.
View in:
PubMed
Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019 Jul; 51(7):1194.
View in:
PubMed
Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2019 06 25; 10(41):4247-4248.
View in:
PubMed
Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412.
View in:
PubMed
Retinoblastoma Loss in Cancer: Casting a Wider Net. Clin Cancer Res. 2019 07 15; 25(14):4199-4201.
View in:
PubMed
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019 May 13; 35(5):817-819.
View in:
PubMed
Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11428-11436.
View in:
PubMed
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. EBioMedicine. 2019 May; 43:114-126.
View in:
PubMed
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 08 01; 125(15):2561-2569.
View in:
PubMed
Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. J Oncol Pract. 2019 06; 15(6):343-345.
View in:
PubMed
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019 04 15; 35(4):603-617.e8.
View in:
PubMed
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019 03 20; 11(484).
View in:
PubMed
Increased Serine and One-Carbon Pathway Metabolism by PKC?/? Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell. 2019 03 18; 35(3):385-400.e9.
View in:
PubMed
Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. Gynecol Oncol Rep. 2019 May; 28:54-57.
View in:
PubMed
Biological Evolution of Castration-resistant Prostate Cancer. Eur Urol Focus. 2019 03; 5(2):147-154.
View in:
PubMed
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harb Perspect Med. 2019 02 01; 9(2).
View in:
PubMed
The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019 08; 60(8):2091-2093.
View in:
PubMed
ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019 01 17; 10(1):278.
View in:
PubMed
Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):584-590.
View in:
PubMed
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 11 01; 128(11):5185.
View in:
PubMed
Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 11; 563(7731):E24.
View in:
PubMed
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Sci Rep. 2018 10 18; 8(1):15442.
View in:
PubMed
CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018; 6:13.
View in:
PubMed
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51.
View in:
PubMed
The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018 Sep 17; 8(3).
View in:
PubMed
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 2018 09 06; 9(1):3600.
View in:
PubMed
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453.
View in:
PubMed
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol. 2018 10; 246(2):244-253.
View in:
PubMed
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018; 2018.
View in:
PubMed
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503.
View in:
PubMed
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 08; 560(7719):499-503.
View in:
PubMed
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO Precis Oncol. 2018; 2.
View in:
PubMed
Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018 06 19; 9(1):2404.
View in:
PubMed
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 06 01; 7(6).
View in:
PubMed
CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. AMIA Jt Summits Transl Sci Proc. 2018; 2017:168-177.
View in:
PubMed
The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651.
View in:
PubMed
Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018 05; 15(5):271-286.
View in:
PubMed
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol. 2018 05; 73(5):687-693.
View in:
PubMed
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 2018 01 01; 29(1):23-25.
View in:
PubMed
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018 03 01; 124(5):1008-1015.
View in:
PubMed
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017 Dec 11; 32(6):792-806.e7.
View in:
PubMed
Rapid autopsy of a patient with recurrent anaplastic ependymoma. Palliat Support Care. 2018 04; 16(2):238-242.
View in:
PubMed
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res. 2017 Nov 15; 23(22):6802-6811.
View in:
PubMed
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211.
View in:
PubMed
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precis Oncol. 2017; 2017.
View in:
PubMed
Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017 Jun 06; 23(6):1-10.
View in:
PubMed
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harb Mol Case Stud. 2017 Sep; 3(5).
View in:
PubMed
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 2017 05 02; 18(1):80.
View in:
PubMed
Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol. 2017 06; 35(6):577-582.
View in:
PubMed
Emerging Variants of Castration-Resistant Prostate Cancer. Curr Oncol Rep. 2017 May; 19(5):32.
View in:
PubMed
On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. Anticancer Res. 2017 04; 37(4):1569-1573.
View in:
PubMed
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov. 2017 05; 7(5):462-477.
View in:
PubMed
The clone wars. Sci Transl Med. 2017 02 15; 9(377).
View in:
PubMed
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017 01 06; 355(6320):84-88.
View in:
PubMed
Unleashing the wrath of Ras. Sci Transl Med. 2017 01 04; 9(371).
View in:
PubMed
Prostate cancer in 2016: Improved outcomes and precision medicine come within reach. Nat Rev Urol. 2017 Feb; 14(2):71-72.
View in:
PubMed
Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. Am Soc Clin Oncol Educ Book. 2017; 37:358-369.
View in:
PubMed
Synthetic lethality and beyond. Sci Transl Med. 2016 11 16; 8(365):365ec182.
View in:
PubMed
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2017 01; 7(1):54-71.
View in:
PubMed
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016 12; 48(12):1490-1499.
View in:
PubMed
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016 10 10; 30(4):563-577.
View in:
PubMed
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genom Med. 2016; 1.
View in:
PubMed
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53.
View in:
PubMed
Update on the biology and management of neuroendocrine prostate cancer. Clin Adv Hematol Oncol. 2016 Jul; 14(7):513-5.
View in:
PubMed
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. Eur Urol. 2017 01; 71(1):68-78.
View in:
PubMed
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3.
View in:
PubMed
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thromb Res. 2016 Apr; 140 Suppl 1:S192.
View in:
PubMed
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016 Mar; 22(3):298-305.
View in:
PubMed
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. Am Soc Clin Oncol Educ Book. 2016; 35:131-41.
View in:
PubMed
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1510-9.
View in:
PubMed
An emerging role for cytopathology in precision oncology. Cancer Cytopathol. 2016 Mar; 124(3):167-73.
View in:
PubMed
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015 Aug 11; 12(6):922-36.
View in:
PubMed
Prostate cancer: Intrapatient heterogeneity in prostate cancer. Nat Rev Urol. 2015 Aug; 12(8):430-1.
View in:
PubMed
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454.
View in:
PubMed
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015 Jul; 1(4):466-74.
View in:
PubMed
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604.
View in:
PubMed
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228.
View in:
PubMed
CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2015 May 20; 6(14):11994-2008.
View in:
PubMed
Prioritizing precision medicine for prostate cancer. Ann Oncol. 2015 Jun; 26(6):1041-1042.
View in:
PubMed
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015; 92-103.
View in:
PubMed
ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014 Nov 25; 5:5548.
View in:
PubMed
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014 Nov 21; 5:5383.
View in:
PubMed
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep 25; 159(1):176-187.
View in:
PubMed
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 2014 Aug 26; 15(8):439.
View in:
PubMed
Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib. Asian J Androl. 2014 Jul-Aug; 16(4):568-9.
View in:
PubMed
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol. 2014 Oct; 45(10):2136-43.
View in:
PubMed
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014 Jun; 38(6):756-67.
View in:
PubMed
Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 01; 20(11):2846-50.
View in:
PubMed
The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014; 4:60.
View in:
PubMed
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. Mol Cancer Res. 2014 Jun; 12(6):815-22.
View in:
PubMed
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014 Feb 15; 74(4):1272-83.
View in:
PubMed
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov; 31(11):1023-31.
View in:
PubMed
Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia. 2013 Jul; 15(7):761-72.
View in:
PubMed
Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
View in:
PubMed
Epigenomic alterations in localized and advanced prostate cancer. Neoplasia. 2013 Apr; 15(4):373-83.
View in:
PubMed
DNA mismatch repair in prostate cancer. J Clin Oncol. 2013 May 10; 31(14):1782-4.
View in:
PubMed
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013 Jan; 15(1):1-10.
View in:
PubMed
New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res. 2013 Feb 01; 19(3):517-23.
View in:
PubMed
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013 Feb 01; 73(3):1232-44.
View in:
PubMed
Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012 Dec 20; 30(36):e386-9.
View in:
PubMed
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013 May; 63(5):920-6.
View in:
PubMed
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012 Jul; 227(3):286-97.
View in:
PubMed
Editorial comment. J Urol. 2012 Jul; 188(1):108-9.
View in:
PubMed
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A. 2012 Apr 24; 109(17):6686-91.
View in:
PubMed
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther. 2012 Mar; 11(3):775-83.
View in:
PubMed
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011 Nov; 1(6):487-95.
View in:
PubMed
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int. 2012 Apr; 109(7):968-85.
View in:
PubMed
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian J Androl. 2011 Nov; 13(6):785-6.
View in:
PubMed
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011 Aug; 60(2):279-90.
View in:
PubMed
Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. Adv Urol. 2010; 179250.
View in:
PubMed
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Feb 15; 116(4 Suppl):1075-83.
View in:
PubMed